IoT Software and Services in Pharmaceutical Sector to Hit $2.4 Billion by 2020, Global Data Forecasts

The Internet of Things (IoT) is transforming the pharmaceutical industry at a rapid pace, according to new research from GlobalData. Indeed, IoT software and services in the pharmaceutical industry is expected to grow from $420 million in 2015 to $2,486 million by 2020, at a Compound Annual Growth Rate (CAGR) of 42.7 percent from 2016 to 2020.

IoT has the potential to enhance almost all the processes of the pharmaceutical industry ranging from clinical trials, drug disclosure, manufacturing, and supply chain to remote patient monitoring, according to the London-based data and analytics company.

 “IoT software and services effortlessly connect and create the base upon which IoT applications and use cases can be realized to develop a comprehensive solution that will benefit organizations to reduce response times, enhance product quality, security, and boost performance,” explains Alok Singh, senior technology analyst at GlobalData.

“IoT software and services spending is driven by the large adoption of cloud platform as a service (PaaS) along with advanced data analytics, new application, and use cases, which transforms data into substantial information and eventually into the activity that will boost business productivity, or better customer service.”

GlobalData’s pharmaceutical IoT software and services revenue forecast depicts significant growth in the Asia-Pacific region, to reach a value of $655 million by 2020, growing almost fivefold against the 2015 baseline.

The Asia-Pacific region’s robust IoT software and services growth in the pharmaceutical sector is primarily driven by the large number of upcoming pharmaceutical manufacturing organizations, increasing expenditure, high internet penetration rates, government investment policies, demand for quality treatment, and rising adoption of new technologies like cloud computing, big data, and artificial intelligence (AI).

Moreover, the Middle East & Africa (MEA) region will deliver the fastest overall growth in IoT spending with a five-year CAGR of 49.9 percent, but from a far smaller base. Meanwhile, North America and Europe are the largest regions in terms of investment at the beginning of the forecast period and combined represent a $1.5 billion market by 2020.

 “IoT will revolutionize the way pharmaceutical organization will operate and do business,” Singh noted. IoT software and services can help pharmaceutical organizations to digitize and connect critical actions, increase efficiencies, compliance, and persuade product quality that will benefit organizations to achieve a faster time to value.”

(For more information visit https://www.globaldata.com).